Navigation Links
CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
Date:6/16/2009

--Orally Active Enhancer of Human Nerve Growth Factor Has Demonstrated Promising Activity Preclinically--

--Broad Potential Applications Include Neuropathies, Alzheimer's and Huntington's Disease and Others--

RESEARCH TRIANGLE PARK, N.C., June 16 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced that it has obtained the rights to develop and market a novel agent for the prevention and treatment of neuropathies and neurodegenerative disorders. The drug candidate, CXB909, is a small molecule, orally active agent that enhances the effects of nerve growth factor (NGF). CeNeRx intends to initiate a Phase l trial of CXB909 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) later this year.

"Nerve growth factor has long been of interest as a potential therapy for neuropathies and neurodegenerative diseases, but recombinant NGF lacks key qualities needed for successful CNS drugs," said Dr. Daniel Burch, Executive Vice President of R&D and Chief Medical Officer of CeNeRx. "In preclinical studies, our small molecule agent CXB909 has been shown to increase the action of native NGF, but without the pharmacokinetic and administration challenges of recombinant NGF. Most notably, CXB909 crosses the blood brain barrier, has a long half-life and is orally available. The preclinical data for this agent is very promising, and we look forward to assessing it in the clinic for neuropathic and neurodegenerative conditions that currently have no treatment options."

CXB909 is a downstream enhancer of the effects of nerve growth factor, an endogenously produced neurotrophic factor that is important for the function and survival of several types of neurons. Both Alzheimer's disease and Huntington's disease involve the degeneration of certain neurons, and n
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
2. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
3. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
4. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
7. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
11. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... NEW YORK and LONDON ... leading distributor of market intelligence, MarketResearch.com is pleased to ... IQ4I Research and Consultancy focusing on the active pharmaceutical ... IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Global Market – Forecast to 2020 , ...
(Date:11/26/2014)... Nov. 25, 2014 Reinforcing its commitment to ... (NYSE: PHG AEX: PHIA) today announced ... (FDA) for its IQon Spectral CT , presenting ... kind technology adds a new dimension to Computed Tomography ... to characterize structures based on their material content within ...
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2
... MADISON, N.J. and AUSTIN, Texas, May 24, 2011 ... Obstetrics & Gynecology demonstrated that adding OVA1 to ... would identify more ovarian cancers than a physician,s preoperative ... this month in the journal, which is the official ...
... May 24, 2011 The Board of Directors of BD (Becton, ... quarterly dividend of 41 cents per common share, payable on June ... indicated annual dividend rate is $1.64 per share. ... leading global medical technology company that develops, manufactures and sells medical ...
Cached Medicine Technology:OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 2OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 3OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 4
(Date:11/27/2014)... 27, 2014 “LAB.C” was featured on NewsWatch ... latest and coolest technology products available to consumers. Mallory Sofastaii, ... product review and shared with viewers the company offers ... Android devices. , Consumers love portability and functionality. A ... Case for the iPhone5 and 5S has a portable USB ...
(Date:11/27/2014)... HealthPostures, a leading national designer ... announced that it has entered into a new ... will put HealthPostures' products into central Indiana’s premiere ... to having its products sold through Commercial Office ... with the business decision makers in the Indianapolis ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. "Every ... as we enjoy the ugly sweater contest." Last year's ... " It was a sight to see. She glued ... the Christmas balls were faces of the staff with Dr. ... this year, it's simple to get in on the fun. ...
(Date:11/27/2014)... Ethane Web Technologies, an ISO 9001: 2008 certified Internet ... discount on PPC service. The discount will be available for ... on 1 December 2014 and remain valid until midnight of ... professional working at Ethane Web Technologies says, "This is a ... big discount would make the service quite affordable for them. ...
(Date:11/27/2014)... November 27, 2014 Serious Buyer, Andrew ... 1969 Jimi Hendrix Tuscaloosa Memorial Coliseum concert posters. Between ... played at the University of Alabama. Jimi Hendrix started ... Hawley, “It started with Gary Weinberger who was a ... University Programs Council. The council was responsible for bringing ...
Breaking Medicine News(10 mins):Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2Health News:Serious Buyer Announces His Search For Vintage 1969 Jimi Hendrix Tuscaloosa Memorial Coliseum Concert Posters 2
... of feline DNA could help humans, too, scientists say , ... genome of the domestic cat ( Felis catus ), an ... popular pets and provide an excellent model for human disease. ... be traced back several generations to Sweden, was the subject ...
... High-blood-pressure patients treated for enlarged heart (left ventricular ... LVH may also have a better chance of ... Cornell Medical Center, the research is published in ... Heart Association (AHA). , An estimated 20 percent ...
... Investments,Inc. (Amex: MGT ), a holding company focused ... plans to present at the Acumen,BioFin Rodman & Renshaw ... in New York City on Wednesday, November 7, at ... of MGT Capital Investments, Inc.,will provide an overview of ...
... Group, Inc. (Nasdaq: COLY ), today announced ... Executive Officer, plans to,provide a corporate update at ... Annual Healthcare Conference at 9:50am ET on November ... Interested parties may access an audio webcast of ...
... de Latinos Unidos, a,U.S. not-for-profit organization and public ... government officials of the Mexican State,of Sonora disclosed ... an,international investigative study focusing on immigrant "dumping" which,began ... practice of U.S. employers and others who,simply deport ...
... A new Mayo Clinic study shows that massage therapy decreases pain ... 2005, 58 patients undergoing surgery participated in a pilot study to ... 30 who received massage, the mean pain scores were less than ... the most painful. , Before the massage therapy, these patients rated ...
Cached Medicine News:Health News:Preventing or reducing enlarged heart may decrease risk for diabetes 2Health News:MGT Capital Investments to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:Latino Advocacy Group Investigates Immigrant 'Dumping' by U.S. Employers 2Health News:Mayo researchers: complementary therapies help patients recover after heart surgery 2Health News:Mayo researchers: complementary therapies help patients recover after heart surgery 3
... The PipetBoy Pipettor is light as a feather ... aspiration speed can be continuously adjusted. The pipette ... be autoclaved. Two dosing knobs enable fine dosing ... plastic an/or glass pipettes from 0.1 to 100 ...
Precise, safe, and fatigue-free series pipetting using graduated pip...
Inquire...
Inquire...
Medicine Products: